{"id":"different-haart-regimens","safety":{"commonSideEffects":[{"rate":"20-40","effect":"Nausea and gastrointestinal disturbance"},{"rate":"10-30","effect":"Lipodystrophy (fat redistribution)"},{"rate":"15-30","effect":"Peripheral neuropathy"},{"rate":"5-15","effect":"Hepatotoxicity"},{"rate":"20-50","effect":"Hyperlipidemia"},{"rate":"<1","effect":"Lactic acidosis (rare)"},{"rate":"10-25","effect":"Immune reconstitution inflammatory syndrome (IRIS)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Highly Active Antiretroviral Therapy (HAART) typically combines nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and/or protease inhibitors (PIs) to simultaneously block reverse transcription and protease-mediated viral maturation. This multi-drug approach prevents the emergence of drug-resistant viral strains and achieves sustained viral suppression, allowing immune reconstitution in HIV-infected patients.","oneSentence":"HAART regimens suppress HIV replication by combining multiple antiretroviral drugs that target different stages of the viral life cycle.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:27:06.944Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection (treatment and viral suppression)"},{"name":"AIDS prevention and management"}]},"trialDetails":[{"nctId":"NCT01236235","phase":"","title":"Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-01","conditions":"HIV","enrollment":525},{"nctId":"NCT00128908","phase":"PHASE4","title":"Sequential HIV Therapy in Treatment Resistant HIV-1 Infected Patients","status":"TERMINATED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2005-09","conditions":"HIV Infections","enrollment":3},{"nctId":"NCT00139178","phase":"PHASE4","title":"Switching From Zidovudine to an NNRTI or Lopinavir/Ritonavir in Patients Treated With Zidovudine/ Lamivudine/Abacavir.","status":"COMPLETED","sponsor":"Danish HIV Research Group","startDate":"2004-03","conditions":"HIV Associated Lipodystrophy Syndrome., HIV, Hypercholesterolemia","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":25,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Different HAART regimens","genericName":"Different HAART regimens","companyName":"Danish HIV Research Group","companyId":"danish-hiv-research-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HAART regimens suppress HIV replication by combining multiple antiretroviral drugs that target different stages of the viral life cycle. Used for HIV-1 infection (treatment and viral suppression), AIDS prevention and management.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}